Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;125(6):511-2.
doi: 10.1016/j.thromres.2009.09.019. Epub 2009 Oct 24.

Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism

David A Manly  1 , Jianguo Wang, Sam L Glover, Raj Kasthuri, Howard A Liebman, Nigel S Key, Nigel Mackman
Affiliations

Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism

David A Manly et al. Thromb Res. 2010 Jun.

Abstract

Cancer patients exhibit a high rate of thromboembolism (VTE). In this study, we analyzed levels of microparticle (MP) tissue factor (TF) activity in cancer patients with or without VTE. Blood was collected from cancer patients within 24 h of objectively diagnosed VTE (n=53) and from cancer patients without VTE (n=13). MPs were isolated from platelet poor plasma by centrifugation at 20,000g for 15 min. MP TF activity was measured using a two-stage chromogenic assay. Cancer patients with VTE had a significantly higher mean MP TF activity compared with cancer patients without VTE (1.7+/-3.8 pg/mL vs 0.6+/-0.4 pg/mL, p<0.05). Further prospective studies are required to determine if levels of MP TF activity may be a useful biomarker to identify patients at increased risk for VTE.

PubMed Disclaimer

Figures

Figure
Figure
Comparison of MP TF activity between cancer patients with VTE (n=53) and cancer patients without VTE (n=13) (Median, Inter-quartile Range, 2 Standard Deviations). Dots represent MP TF activity levels beyond 2 standard deviations.
See this image and copyright information in PMC

References

    1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Thromb Haemost. 2007;5(3):632–4. - PubMed
    1. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006 Feb;17(2):297–303. - PubMed
    1. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) Blood. 2008 Oct 1;112(7):2703–8. - PubMed
    1. Cosmi B, Legnani C, Cini M, et al. The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. Haematologica. 2005 May;90(5):713–5. - PubMed
    1. Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007 Jan 29;96(2):290–5. - PMC - PubMed

Publication types